Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)

Next Previous
Trial Profile

Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms COLUMBUS-AMD
  • Sponsors Bioeq

    • Most Recent Events

    • 29 Aug 2022 According to Polpharma Biologics media release, the European Commission has granted marketing authorization to Ranivisio ,a biosimilar to Lucentis, for the treatment for several serious retinal diseases in the EU, EC approval follows positive opinion issued in Jun 2022 by the CHMP of the EMA and is applicable to all 27 EU member states plus Iceland, Norway and Liechtenstein; EU-approval is based on the totality of evidence including analytical, nonclinical, clinical and manufacturing data
    • 03 Aug 2022 According to a Food and Drug Administration media release, the U.S. Food and Drug Administration ("FDA") has approved CIMERLI™ (ranibizumab-eqrn) for the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV).
    • 02 Aug 2022 According to a Food and Drug Administration media release, the USFDA has approved CIMERLI as a biosimilar product interchangeable with Lucentis for all five indications, with 12 months of interchangeability exclusivity based on this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top